Clinical results have spoken, funding sorted... time for approval and then we start pulling in the revenue late next year. Uptake should be rapid once approval is achieved.
RMAT designated CHF program soon about to take over the headlines.
Run by the NIH, credibility of our science is about to be catapulted into mainstream US healthcare market.
Ann: Day 180 Survival Outcomes In aGvHD Phase 3 Trial, page-14
-
- There are more pages in this discussion • 66 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 15000 | $1.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.19 | 75212 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |